Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
Status:
Unknown status
Trial end date:
2020-04-15
Target enrollment:
Participant gender:
Summary
The purpose of this prospective study is to determine the efficacy and safety of Rituximab
plus Bortezomib in patients with newly diagnosed acquired hemophilia A.